glp-1 drugs for parkinson's disease The Emerging Role of RAs in GLP-1 drug shows little benefit

Claims of pharmaceutical grade

[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Knop FK, et al

We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development

Victozas prescribing information does include warnings about pancreatitis, and regulatory updates have focused on monitoring and communication rather than definitive cancer causation findings

PMCID: PMC4141528 ) Aster RH, Curtis BR, McFarland JG, Bougie DW (2009) Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management

Recombinant L lactis has been successful in delivering anti-inflammatory cytokines and other therapeutic molecules for conditions like inflammatory bowel disease and oral mucositis and reversing type 1 diabetes